FY2018 EPS Estimates for Zimmer Biomet Holdings Inc Reduced by Analyst (ZBH)

Zimmer Biomet Holdings Inc (NYSE:ZBH) – Piper Jaffray Companies lowered their FY2018 earnings per share estimates for Zimmer Biomet in a research note issued on Sunday, October 28th. Piper Jaffray Companies analyst M. O’brien now expects that the medical equipment provider will post earnings per share of $7.63 for the year, down from their prior estimate of $7.68. Piper Jaffray Companies has a “Neutral” rating and a $120.00 price target on the stock. Piper Jaffray Companies also issued estimates for Zimmer Biomet’s Q2 2019 earnings at $1.97 EPS, Q3 2019 earnings at $1.74 EPS, FY2019 earnings at $7.80 EPS and FY2020 earnings at $8.36 EPS.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Friday, October 26th. The medical equipment provider reported $1.63 EPS for the quarter, topping the consensus estimate of $1.60 by $0.03. The business had revenue of $1.84 billion during the quarter, compared to the consensus estimate of $1.84 billion. Zimmer Biomet had a net margin of 22.42% and a return on equity of 12.88%. Zimmer Biomet’s revenue was up 1.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.72 EPS.



Other analysts also recently issued research reports about the stock. Needham & Company LLC downgraded shares of Zimmer Biomet from a “strong-buy” rating to a “buy” rating and set a $150.00 target price for the company. in a report on Monday, August 13th. Jefferies Financial Group lifted their target price on shares of Zimmer Biomet to $145.00 and gave the stock a “buy” rating in a report on Monday, July 30th. Oppenheimer reaffirmed a “buy” rating and set a $138.00 target price (up previously from $130.00) on shares of Zimmer Biomet in a report on Friday, July 27th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $150.00 target price on shares of Zimmer Biomet in a report on Monday, August 27th. Finally, ValuEngine raised shares of Zimmer Biomet from a “sell” rating to a “hold” rating in a report on Wednesday, July 25th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and fifteen have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $133.86.

Shares of ZBH stock opened at $114.58 on Tuesday. The stock has a market cap of $23.43 billion, a P/E ratio of 14.27, a P/E/G ratio of 2.11 and a beta of 1.08. The company has a quick ratio of 0.96, a current ratio of 1.89 and a debt-to-equity ratio of 0.70. Zimmer Biomet has a 52 week low of $104.28 and a 52 week high of $134.55.

Large investors have recently modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. raised its position in shares of Zimmer Biomet by 5,200.0% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,007 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 988 shares in the last quarter. Regent Investment Management LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $201,000. Azimuth Capital Management LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $201,000. Aries Wealth Management acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $202,000. Finally, HighPoint Advisor Group LLC acquired a new position in shares of Zimmer Biomet in the 3rd quarter valued at approximately $202,000. Institutional investors own 86.58% of the company’s stock.

In other Zimmer Biomet news, VP Chad F. Phipps sold 30,100 shares of Zimmer Biomet stock in a transaction dated Friday, September 21st. The shares were sold at an average price of $132.37, for a total value of $3,984,337.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bryan C. Hanson acquired 410 shares of the company’s stock in a transaction on Friday, August 31st. The stock was acquired at an average price of $123.03 per share, with a total value of $50,442.30. Following the purchase, the chief executive officer now directly owns 25,487 shares in the company, valued at $3,135,665.61. The disclosure for this purchase can be found here. 0.71% of the stock is owned by insiders.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 31st. Shareholders of record on Friday, September 28th will be paid a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.84%. The ex-dividend date of this dividend is Thursday, September 27th. Zimmer Biomet’s dividend payout ratio (DPR) is 11.96%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Featured Article: What is insider trading?

Earnings History and Estimates for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply